China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.46
(-0.18%)
HKD 5.46
(-0.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.14 Billion HKD | 10.25% |
| 2022 | 10.81 Billion HKD | 16.91% |
| 2021 | 9.24 Billion HKD | 9.19% |
| 2020 | 8.47 Billion HKD | 5.56% |
| 2019 | 8.02 Billion HKD | -23.17% |
| 2018 | 10.44 Billion HKD | 12.45% |
| 2017 | 9.28 Billion HKD | 11.59% |
| 2016 | 8.32 Billion HKD | 5.63% |
| 2015 | 7.87 Billion HKD | -10.98% |
| 2014 | 8.85 Billion HKD | 3.96% |
| 2013 | 8.51 Billion HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 7.56 Billion HKD | 0.0% |
| 2023 Q4 | 4.25 Billion HKD | 0.0% |
| 2023 FY | 11.92 Billion HKD | 10.25% |
| 2023 Q2 | 7.03 Billion HKD | 0.0% |
| 2022 Q2 | 6.62 Billion HKD | 0.0% |
| 2022 FY | 10.81 Billion HKD | 16.91% |
| 2022 Q4 | 4.18 Billion HKD | 0.0% |
| 2021 Q2 | 5.4 Billion HKD | 0.0% |
| 2021 Q4 | 3.83 Billion HKD | 0.0% |
| 2021 FY | 9.24 Billion HKD | 9.19% |
| 2020 FY | 8.47 Billion HKD | 5.56% |
| 2020 Q4 | 3.45 Billion HKD | 0.0% |
| 2020 Q2 | 5.01 Billion HKD | 0.0% |
| 2019 Q2 | 5.47 Billion HKD | 0.0% |
| 2019 FY | 8.02 Billion HKD | -23.17% |
| 2019 Q4 | 2.54 Billion HKD | 0.0% |
| 2018 FY | 10.44 Billion HKD | 12.45% |
| 2018 Q2 | 5.65 Billion HKD | 0.0% |
| 2018 Q4 | 4.78 Billion HKD | 0.0% |
| 2017 FY | 9.28 Billion HKD | 11.59% |
| 2017 Q2 | 4.89 Billion HKD | 0.0% |
| 2017 Q4 | 4.38 Billion HKD | 0.0% |
| 2016 FY | 8.32 Billion HKD | 5.63% |
| 2016 Q4 | 3.83 Billion HKD | 0.0% |
| 2016 Q2 | 4.48 Billion HKD | 0.0% |
| 2015 Q2 | 4.7 Billion HKD | 0.0% |
| 2015 FY | 7.87 Billion HKD | -10.98% |
| 2015 Q4 | 3.17 Billion HKD | 0.0% |
| 2014 Q4 | 1.71 Billion HKD | 10.58% |
| 2014 Q3 | 1.55 Billion HKD | 0.0% |
| 2014 Q2 | 1.55 Billion HKD | 0.0% |
| 2014 Q1 | 1.55 Billion HKD | 0.0% |
| 2014 FY | 8.85 Billion HKD | 3.96% |
| 2013 Q3 | 1.46 Billion HKD | 0.0% |
| 2013 FY | 8.51 Billion HKD | 0.0% |
| 2013 Q2 | 1.46 Billion HKD | 0.0% |
| 2013 Q1 | 1.46 Billion HKD | 0.0% |
| 2013 Q4 | 1.55 Billion HKD | 5.84% |
| 2012 Q4 | 1.46 Billion HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -8393.745% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | -356.074% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 148924.725% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -29613.978% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 23377.838% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -33602.553% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -3814.246% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 18491.839% |
| SSY Group Limited | 1.63 Billion HKD | -641.172% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -6872.862% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -3546.39% |